Jianjun Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1375895/publications.pdf

Version: 2024-02-01

		81900	40979
136	10,176	39	93
papers	citations	h-index	g-index

152	152	152	13981
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology, 2022, 40, 702-709.	1.6	53
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	1.1	151
3	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	2.0	2
4	A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Medicine, 2022, 14, 5.	8.2	25
5	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	2.6	2
6	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 2022, 30, 100514.	1.7	5
7	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
8	Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers, 2022, 14, 824.	3.7	2
9	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
10	Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 526-539.	7.0	39
11	Abnormal global alternative RNA splicing in COVID-19 patients. PLoS Genetics, 2022, 18, e1010137.	3.5	21
12	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. British Journal of Cancer, 2022, 127, 569-576.	6.4	8
13	Targeting IL-1Î² as an immunopreventive and therapeutic modality for K-rasâ€“mutant lung cancer. JCI Insight, 2022, 7, .	5.0	25
14	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	8.6	2
15	Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC.. Journal of Clinical Oncology, 2022, 40, 9061-9061.	1.6	0
16	Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic nonâ€“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055.	1.6	0
17	Auto-reactive antibodies as predictive markers for immune checkpointâ€“induced pneumonitis.. Journal of Clinical Oncology, 2022, 40, 2554-2554.	1.6	1
18	Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.. Journal of Clinical Oncology, 2022, 40, 9046-9046.	1.6	0

#	Article	IF	Citations
19	Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.. Journal of Clinical Oncology, 2022, 40, 9049-9049.	1.6	1
20	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	5.9	15
21	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	17.5	31
22	Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9105-9105.	1.6	3
23	Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21169-e21169.	1.6	0
24	Molecular parameters impacting the success rate of a lung cancer PDX model.. Journal of Clinical Oncology, 2022, 40, e20592-e20592.	1.6	0
25	Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell, 2022, 40, 754-767.e6.	16.8	34
26	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers, 2022, 14, 3473.	3.7	5
27	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	2.6	10
28	Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene, 2021, 40, 821-832.	5.9	14
29	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.8	14
30	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	1.1	48
31	Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	3.2	40
32	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	12.8	30
33	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
34	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	3.7	7
35	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	14.3	80
36	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62

#	Article	IF	Citations
37	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 601-609.	1.1	40
38	Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.. Journal of Clinical Oncology, 2021, 39, 8528-8528.	1.6	5
39	PI3K-AKT pathway alterations are revealed as a potential mechanism of chemoradiation resistance in small cell lung cancer by whole-exome sequencing.. Journal of Clinical Oncology, 2021, 39, e20573-e20573.	1.6	0
40	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discovery, 2021, 11, 2506-2523.	9.4	68
41	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	12.8	74
42	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
43	Clinical Outcomes in Nonâ€“Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precision Oncology, 2021, 5, 1241-1249.	3.0	11
44	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
45	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	27.8	185
46	Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1180-1192.	5.6	37
47	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer, 2021, 160, 50-58.	2.0	14
48	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	4.2	14
49	STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research, 2021, 27, 1720-1733.	7.0	44
50	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports, 2021, 2, 100237.	1.1	8
51	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	0
52	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
53	The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers. Lung Cancer: Targets and Therapy, 2021, Volume 12, 139-149.	2.7	0
54	Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence. Nature Machine Intelligence, 2021, 3, 1081-1089.	16.0	30

#	Article	IF	Citations
55	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Nonâ€“Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology, 2021, 5, 1802-1812.	3.0	9
56	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	12.8	16
57	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	6
58	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	7.0	80
59	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International Journal of Cancer, 2020, 146, 1359-1368.	5.1	55
60	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 358-366.	1.3	9
61	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 37-46.e7.	2.6	44
62	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 349-357.	0.8	27
63	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	7.0	30
64	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	5.9	29
65	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	2.0	12
66	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. Journal of Thoracic Oncology, 2020, 15, 1919-1927.	1.1	53
67	Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers, 2020, 12, 1903.	3.7	0
68	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clinical Cancer Research, 2020, 26, 5477-5486.	7.0	15
69	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	8.8	36
70	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
71	Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death and Disease, 2020, 11, 346.	6.3	102
72	What Do Patients With Nonâ€“Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncology Practice, 2020, 16, e1151-e1160.	2.9	8

#	Article	IF	Citations
73	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS ONE, 2020, 15, e0234505.	2.5	25
74	Extracellular vesicle tetraspanin-8 level predicts distant metastasis in nonâ€“small cell lung cancer after concurrent chemoradiation. Science Advances, 2020, 6, eaaz6162.	10.3	42
75	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. Frontiers in Oncology, 2020, 10, 626.	2.8	17
76	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
77	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. Journal of Thoracic Disease, 2020, 12, 1952-1959.	1.4	6
78	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3525-3536.	7.0	22
79	Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver International, 2020, 40, 1997-2007.	3.9	16
80	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. Journal of Thoracic Disease, 2020, 12, 329-337.	1.4	4
81	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
82	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
83	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
84	Clinical potential of ctDNA-based TMB in small cell lung cancer recieving chemoradiotherapy.. Journal of Clinical Oncology, 2020, 38, 3536-3536.	1.6	2
85	Discovery of a novel shared tumor antigen in human lung cancer.. Journal of Clinical Oncology, 2020, 38, 3087-3087.	1.6	0
86	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
87	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
88	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
89	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
90	Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 2208-2211.	1.4	13

#	Article	IF	Citations
91	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	12.8	91
92	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, 1912-1923.	1.1	105
93	Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 5076.	12.8	30
94	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	1.6	882
95	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	1.1	79
96	Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine, 2019, 42, 296-303.	6.1	15
97	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Modern Pathology, 2019, 32, 1053-1064.	5.5	40
98	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	9.4	231
99	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist, 2019, 24, 772-782.	3.7	38
100	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clinical Lung Cancer, 2019, 20, 30-36.e3.	2.6	37
101	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€“small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47.	2.6	45
102	Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).. Journal of Clinical Oncology, 2019, 37, 6009-6009.	1.6	8
103	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9017-9017.	1.6	9
104	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14047-e14047.	1.6	1
105	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	5.5	56
106	TRACERx: Tracking tumor evolution to impact the course of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1199-1202.	0.8	14
107	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Nonâ€“Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 2018, 13, 779-791.	1.1	53
108	Reply to Lambros et al. Modern Pathology, 2018, 31, 541-542.	5.5	0

#	Article	IF	Citations
109	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Modern Pathology, 2018, 31, 307-312.	5.5	24
110	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	7.0	292
111	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
112	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	12.8	122
113	Effect of neoadjuvant chemotherapy on the immune microenvironment in nonâ€“small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
114	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	5.1	31
115	Abstract 4686: T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. , 2018, , .		2
116	Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9052-9052.	1.6	35
117	Association of the T-cell receptor landscape with survival in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 140-140.	1.6	4
118	Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse. , 2018, , .		3
119	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	19
120	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Research, 2017, 77, 6119-6130.	0.9	92
121	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
122	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2017, 112, 90-95.	2.0	188
123	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 770-777.	0.8	16
124	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 141-148.	2.6	12
125	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017, 19, vi40-vi41.	1.2	0
126	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9083-9083.	1.6	1

#	Article	IF	Citations
127	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget, 2017, 8, 21994-22002.	1.8	39
128	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer, 2016, 122, 534-545.	4.1	62
129	MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biology, 2016, 17, 178.	8.8	231
130	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	10.7	865
131	Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications, 2016, 7, 13200.	12.8	132
132	Image Analysisâ€“based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Nonâ€“small Cell Lung Carcinoma Patients. Clinical Cancer Research, 2016, 22, 6278-6289.	7.0	130
133	Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation. Cancer Treatment Communications, 2015, 4, 34-36.	0.4	14
134	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
135	Relationship Between Tumor Size and Survival in Nonâ€“Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal of Thoracic Oncology, 2015, 10, 682-690.	1.1	133
136	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 2014, 346, 256-259.	12.6	834